Land: Malaysia
Språk: engelsk
Kilde: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
MONTELUKAST SODIUM
RANBAXY (MALAYSIA) SDN. BHD.
MONTELUKAST SODIUM
3x10tablet Tablets; 6x10tablet Tablets; 10x10tablet Tablets
RANBAXY (MALAYSIA) SDN. BHD.
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _ AIRLUKAST TABLETS MONTELUKAST SODIUM TABLETS( 10 MG)_ _ Page 1 WHAT IS IN THIS LEAFLET 1. What AIRLUKAST TABLETS is used for 2. How AIRLUKAST TABLETS works 3. Before you use AIRLUKAST TABLETS 4. How to use AIRLUKAST TABLETS 5. While you are using it 6. Side Effects 7. Storage and disposal of AIRLUKAST TABLETS 8. Product description 9. Manufacturer and Product registration holder 10. Date of revision All medicines have risks and benefits. Your doctor has weighed the risks of you taking AIRLUKAST TABLETS against the benefits it is expected to have for you. If you have any concerns about taking this medicine, ask your doctor or pharmacist. Keep this leaflet with the medicine. You may need to read it again. WHAT AIRLUKAST TABLETS IS USED FOR AIRLUKAST TABLETS is used for prevention and treatment of asthma in adults relief of day time and night time symptoms of seasonal allergic rhinitis in adults. Symptoms of asthma include coughing, wheezing and chest tightness. Not all people with asthma wheeze. For some, coughing may be the only symptom of asthma. Symptoms often occur during the night or after exercise. Seasonal allergic rhinitis (also known as hay fever) is an allergic response often caused by airborne pollens from trees, grasses, and weeds. The daytime and nighttime symptoms of seasonal allergic rhinitis typically may include: stuffy, runny, itchy nose; sneezing; watery, swollen, red, itchy eyes. HOW AIRLUKAST TABLETS WORKS AIRLUKAST TABLETS contain the active ingredient, montelukast which is a leukotriene receptor antagonist that blocks substances called leukotrienes. Leukotrienes cause narrowing and swelling of airways in your lungs. By blocking leukotrienes, montelukast improves asthma symptoms, helps control asthma and improves seasonal allergic rhinitis symptoms. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY AIRLUKAST TABLETS HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. This medicine is available only wit Les hele dokumentet
pg. 1 _For the use only of a Registered Medical Practitioner _ PRESCRIBING INFORMATION AIRLUKAST TABLETS (Montelukast Sodium Tablets 10 mg) COMPOSITION Each film coated tablet contains: Montelukast Sodium equivalent to Montelukast ………………………10 mg PRODUCT DESCRIPTION Beige to light yellow coloured, rounded square, film-coated tablets, engraved with ‘10’ on one side and scored on the other side. DESCRIPTION AIRLUKAST contain montelukast sodium, which is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT 1 receptor. It is chemically described as [R-(E)]- 1-[[[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl] phenyl]-3-[2-(1-hydroxy-1-methyl ethyl)phenyl]propyl]thio]methyl]cyclopropane acetic acid, monosodium salt. Its empirical formula is C 35 H 35 ClNNaO 3 S, and its molecular weight is 608.18. The structural formula is: MONTELUKAST SODIUM PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES PHARMACODYNAMICS The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells pg. 2 (including eosinophils and certain myeloid stem cells). CysL Ts have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. In allergic rhinitis, CysL Ts are released from the nasal mucosa after allergen exposure during both early-and late-phase reactions and are associated with symptoms of allergic rhinitis. Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT1 receptor (in preference to other pharmacologically important airway recep Les hele dokumentet